FindTrial
Sign In

A Phase 2 study to evaluate the efficacy and safety of T-817MA in patients with Alzheimer's Disease.

A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with Alzheimer's Disease.

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222449
Enrollment
Unknown
Registered
2014-04-02
Start date
2014-04-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

investigational material(s) Generic name etc : T-817MA INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for In

Sponsors

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients, whose age is between 55 and 90, taking donepezil hydrochloride, and diagnosed as mild to moderate Alzheimer's Disease according to the diagnostic criteria

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026